human X-ray result chartPhoto by Harlie Raethel

May 27 2024 12:00:23 — Fresenius Kabi’s denosumab biosimilar BLA for osteoporosis and cancer-related bone loss treatment accepted by FDA for review.

This BLA submission acceptance is the latest development in Fresenius Kabi’s continuing commitment to improving patient access to high-quality biological products through expanding its biosimilars development capabilities and product portfolio.

By Lisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *

GDPR Cookie Consent with Real Cookie Banner